Clinical Trial Update: Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 dose‑response trial evaluating PF-00217830 versus placebo in acute exacerbation of schizophrenia to assess safety, efficacy, and pharmacokinetics has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• PF-00217830

Snippet

Sponsor: Pfizer | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED